Christian Domingo Xavier Pomares Anisi Morón Ana Sogo
10.3389/fphar.2020.587621
Front Pharmacol
2020 Sep 30;11:587621.
t2 immune responses th2 (type-2) immune responses combined therapy mepolizumab omalizumab severe asthma
CC BY
https://pubmed.ncbi.nlm.nih.gov/33101041/
Case Reports
PMC7556278
33101041
Dual Monoclonal Antibody Therapy for a Severe Asthma Patient
2020